Recent studies into retatrutide peptide demonstrate promising outlook for treating weight and type 2 disease. The compound, a dual agonist of glucagon-like peptide-1 and GIP receptor, seems to provide enhanced weight loss and glycemic regulation versus existing Retatrutide research peptide treatments. Additional clinical trials are required to comp